Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 15.88%, near the low end of its 5-year range (0.00%–38.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 23.68%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
23.68%
DEBT TO ASSETS RATIO AVG 3Y
21.71%
DEBT TO ASSETS RATIO AVG 5Y
15.88%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Passage Bio, Inc.
Market Cap
$13.27M
Debt to Assets Ratio
0.00%
TTM Avg
23.68%
3Y Avg
21.71%
5Y Avg
15.88%
Market Cap
$13.22M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.61M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.72M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.80M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.81M
Debt to Assets Ratio
0.34%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.63M
Debt to Assets Ratio
0.69%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.51M
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Passage Bio, Inc. (PASG) | $13.27M | 0.00% | 23.68% | 21.71% | 15.88% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.22M | 0.05% | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.14M | 0.10% | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.61M | 0.20% | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.72M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.80M | 0.29% | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $13.81M | 0.34% | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.63M | 0.69% | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.51M | 0.30% | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
1.22
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 15.78% |
| 2025-12-31 | 38.55% |
| 2025-09-30 | 32.82% |
| 2025-06-30 | 31.23% |
| 2025-03-31 | 29.20% |
| 2024-12-31 | 24.88% |
| 2024-09-30 | 23.10% |
| 2024-06-30 | 20.86% |
| 2024-03-31 | 18.84% |
| 2023-12-31 | 17.47% |
| 2023-09-30 | 15.67% |
| 2023-06-30 | 13.80% |
| 2023-03-31 | 12.64% |
| 2022-12-31 | 11.13% |
| 2022-09-30 | 10.11% |
| 2022-06-30 | 9.17% |
| 2022-03-31 | 8.27% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2018-12-31 | 0.00% |
